Amesh A. Adalja, MD, FIDSA argues that a bill being considered in the Pennsylvania state legislature will ultimately result in increased antibiotic resistance and will set back the clock for finding appropriate treatments for Lyme disease.
Many health care facilities are looking to expand the use of broad-spectrum sporicidal disinfectants beyond patient isolation rooms to better address the role of the environment in pathogen transmission and acquisition.
Here is an update on the latest research and clinical management.
This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.
Contagion® Editorial Advisory Board member, Khalid Eljaaly, PharmD, BCPS, CAPP, discusses key updates in the Infectious Diseases Society of America and the American Thoracic Society recommendations.
The National Institutes of Health has awarded a 4-year, $4.8 million grant to the University of Arizona to speed up the development of delta-CPS1, a vaccine candidate to fight valley fever.
This time of year means new trainees will begin their careers and are excited to take on research projects. However, they may have limited to no experience in this area. Here is an opportunity to give them structure and guidance when committing to longitudinal trainee research.
Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.
In the latest issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the continuous antibiotic trade-off of targeted vs broad spectrum therapies and cheap vs expensive options as they relate to UTI treatment.
In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.
We review current and emerging treatment options for infections caused by the difficult-to-treat, intrinsically multidrug-resistant organism Stenotrophomonas maltophilia.
This virus has multiple facets and highlights a need for real-time learning.
“A bite bug in the belly.”
Despite having emerged as either the third or fourth leading cause of blood stream infections in the United States, the threat of multi-drug resistant Candida species remains an underappreciated concern.
Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.
This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.
Government agencies and researchers continue to monitor the potentially troubling trend.
A survey of 571 US hospitals regarding practices used to prevent Clostridium difficile infection indicates that nearly half of the facilities appear to not be taking steps to prevent the infection that kills nearly 30,000 people and sickens hundreds of thousands more each year, despite strong evidence that these steps work.
The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.
Quick recognition is key to early initiation of treatment and long-term survival.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
New agents are in development, but none represent a magic bullet for the problems that CRE infections present.
The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.
Growing evidence suggests that antimicrobials also interact with host innate immunity to provide potent indirect effects which enhance bacterial clearance and may result in more rapid and complete effects
A novel study from Seddon and colleagues adds to the body of evidence that supports what antimicrobial stewardship programs are so often challenged to do, early de-escalation.
Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.